IMMunological resPonse Assessment afteR Acute iSchemic Stroke Treated With Endovascular Therapy (IMPRESS)

Sponsor

Fondation Ophtalmologique Adolphe de Rothschild (Other)

Overall Status

Not yet recruiting

CT.gov ID

NCT04663399

Collaborator

(none)

400

Enrollment

Anticipated Duration (Months)

Study Details

Study Description

Brief Summary

IMPRESS study aims to describe the immuno-inflammatory and thrombo-inflammatory profiles during the first 24/36 hours of treatment of patients suffering from AIC treated with TM, and to study the possible impact of these profiles on the functional prognosis at 3 months of AIC treatment.

Condition or Disease	Intervention/Treatment	Phase
Ischemic Stroke Thrombectomy	Other: Prospective patient

Study Design

Study Type:

Observational

Anticipated Enrollment :

400 participants

Observational Model:

Cohort

Time Perspective:

Prospective

Official Title:

IMMunological resPonse Assessment afteR Acute iSchemic Stroke Treated With Endovascular Therapy

Anticipated Study Start Date :

Oct 15, 2022

Anticipated Primary Completion Date :

Aug 15, 2023

Anticipated Study Completion Date :

Sep 15, 2024

Outcome Measures

Primary Outcome Measures

Immuno-inflammatory and thrombo-inflammatory profiles in patients suffering from AIC and treated with mechanical Thrombectomie. [21 months]
Blood plasma collected from patients at inclusion, and at 24 hours +/- 12 hours of the reperfusion treatment will be used to discover and validate panels of inflammatory biomarkers that are predictive of therapeutic response. The biomarkers will be measured using a multiplex preconfigured panels for inflammatory biomarkers.

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years to 90 Years

Sexes Eligible for Study:

All

Inclusion Criteria:

Presenting an acute ischemic stroke for which treatment by mechanical thrombectomy is indicated according to European and North American recommendations (associated or not with intravenous thrombolysis)

Exclusion Criteria:

Intracranial haemorrhage associated with acute ischemic stroke on initial imaging
Contraindication or non-indication to a mechanic thrombectomy
Immunosuppressive treatment or corticosteroid therapy on admission of the patient
Pre-existing neurological disability limiting the neurological assessment to 3 months (mRS>2 on admission)
Dementia known and diagnosed pre-existing at acute ischemic stroke
Pregnant or breastfeeding woman

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

Fondation Ophtalmologique Adolphe de Rothschild

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

Responsible Party:

Fondation Ophtalmologique Adolphe de Rothschild

ClinicalTrials.gov Identifier:

NCT04663399

Other Study ID Numbers:

BMR_2020_32

First Posted:

Dec 11, 2020

Last Update Posted:

Apr 22, 2022

Last Verified:

Apr 1, 2022

Studies a U.S. FDA-regulated Drug Product:

Studies a U.S. FDA-regulated Device Product:

Additional relevant MeSH terms:

Study Results

No Results Posted as of Apr 22, 2022